Medicines labeled for the same conditions

Alternatives to romidepsin

36 other medicines are given the same way (intravenous) and in the same FDA class as romidepsin or labeled mainly for the same use (leukemia, lymphoma and myeloma); 1 is in its class, histone deacetylase inhibitors: belinostat; the others include 5 nucleoside metabolic inhibitors, 4 alkylating drugs and 4 anthracycline topoisomerase inhibitors (FDA labels read October 8, 2026).

Which medicines are labeled for the same conditions as romidepsin?

The first 24 of the 36, the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA class	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Boxed warning	Shortage
Romidepsinhistone deacetylase inhibitor	this medicine	1 labeler	n/a	No	No current entry
Belinostathistone deacetylase inhibitor · same class	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Cyclophosphamidealkylating drug	Leukemia, lymphoma and myeloma	15 labelers	n/a	No	No current entry
Doxorubicinanthracycline topoisomerase inhibitor	Leukemia, lymphoma and myeloma	16 labelers	n/a	Yes	No current entry
Bortezomibproteasome inhibitor	Leukemia, lymphoma and myeloma	22 labelers	n/a	No	No current entry
Arsenic trioxide	Leukemia, lymphoma and myeloma	16 labelers	n/a	Yes	A presentation being discontinued
Bendamustinealkylating drug	Leukemia, lymphoma and myeloma	4 labelers	n/a	No	A presentation being discontinued
Nelarabinenucleoside metabolic inhibitor	Leukemia, lymphoma and myeloma	12 labelers	n/a	Yes	No current entry
Idarubicinanthracycline topoisomerase inhibitor	Leukemia, lymphoma and myeloma	2 labelers	n/a	Yes	No current entry
Clofarabinenucleoside metabolic inhibitor	Leukemia, lymphoma and myeloma	9 labelers	n/a	No	No current entry
Melphalanalkylating drug	Leukemia, lymphoma and myeloma	6 labelers	n/a	Yes	A presentation being discontinued
Rituximabcd20-directed cytolytic antibody	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	No current entry
Fludarabinenucleoside metabolic inhibitor	Leukemia, lymphoma and myeloma	6 labelers	n/a	Yes	No current entry
Pralatrexatefolate analog metabolic inhibitor	Leukemia, lymphoma and myeloma	1 labeler	n/a	No	No current entry
Daunorubicinanthracycline topoisomerase inhibitor	Leukemia, lymphoma and myeloma	2 labelers	n/a	Yes	No current entry
Carmustinealkylating drug	Leukemia, lymphoma and myeloma	3 labelers	n/a	Yes	No current entry
Cytarabinenucleoside metabolic inhibitor	Leukemia, lymphoma and myeloma	2 labelers	n/a	Yes	No current entry
Mitoxantronetopoisomerase inhibitor	Leukemia, lymphoma and myeloma	3 labelers	n/a	Yes	No current entry
Carfilzomibproteasome inhibitor	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Daratumumabcd38-directed cytolytic antibody	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Elotuzumabslamf7-directed immunostimulatory antibody	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Glofitamabbispecific cd20-directed cd3 t cell engager	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	No current entry
Isatuximabcd38-directed cytolytic antibody	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry
Mosunetuzumab	Leukemia, lymphoma and myeloma	none listed	n/a	Yes	No current entry
Tafasitamab	Leukemia, lymphoma and myeloma	none listed	n/a	No	No current entry

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Romidepsin: the full record: label, generics, price, shortages, recalls